Skip to main content
All lobbying filings

CENCORA, INC.

Lobbying for CENCORA, INC.

 Filing · LD-2 quarterly report Q3 report
Reporting period
3rd Quarter 2026
July 1 - Sep 30 · Posted Oct 20, 2026
Expenses
$405,804
What this organization spent lobbying with its own staff. Reported using the LDA's own definitions (method A): the three LDA methods count different costs, so an expenses figure is not comparable across filers that used different ones.
Client based in
District of Columbia

Official filing document

 Government bodies contacted 6

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

 Lobbying activity 5

Ensuring Community Access to Pharmacist Services Act (H.R. 3164)/ Main Street Pharmacy Access Act (H.R. 3164)/ Equitable Community Access to Pharmacist Services Act  (S.2426) Inflation Reduction Act implementation, including impact on Pharmacy & Physician Reimbursement Protecting Patient Access to Cancer and Complex Therapies Act 2025 (H.R 4299) Reimbursement policies impacting drug shortages Part B drug pricing changes Preventing and mitigating generic drug shortages CMS FY 2026 Medicare Part B Physician Fee Schedule Medicare physician reimbursement CY2026 Medicare Physician Fee Schedule Rule CMS FY 2027 Medicare Physician Fee Schedule Distributor bona fide service fees Patients First Act of 2026 (H.R.9693)

Preventing and mitigating generic drug shortages Ensuring Seniors Access to Critical Medications Act/ Main Street Pharmacy Access Act (H.R. 3164)/Equitable Community Access to Pharmacist Services Act  (S.2426) Impacts to pharmacy Part D drug pricing in Inflation Reduction Act (IRA) Support for Fair Pharmacy Reimbursement

Essential Medicines Strategic Stockpile Department of Defense Essential Medicines Strategic Stockpile Prescription Information Modernization Act (H.R.4132/S.2027) Mitigation of Drug Shortages Pharmaceutical supply chain resilience National Defense Authorization Act for Fiscal Year 2027 (NDAA - H.R.8800/S.4784) Supply Chain Resiliency Most Favored Nation drug pricing proposals Direct to consumer pharmacy proposals CMS FY 2026 Medicare Part B Physician Fee Schedule Rule Break Up Big Medicine Act (S. 3822) Stop Corporate Take Over of Physicians Act (H.R.10444/S.5419) Role and value of community specialty physicians and Management Services Organizations (MSOs) NIH Restructuring/National Eye Institute Pandemic and All-Hazards Preparedness/Protecting Americans from All Hazards Preparedness Act (PAHPA) Protecting Patient Access to Cancer and Complex Therapies Act (H.R. 4299)

Net CFC Tested Income (NCTI) US Territories Reshoring Tax Policy

Tariff proposed policies H.R.2213 - Medical Supply Chain Resiliency Act

 Bills named in this filing 12
  • H.R. 3164
    Ensuring Community Access to Pharmacist Services Act
  • S. 2426
    Equitable Community Access to Pharmacist Services Act
  • H.R. 4299
    Protecting Patient Access to Cancer and Complex Therapies Act
  • H.R. 9693
    Patients First Act of 2026
  • H.R. 4132
    Prescription Information Modernization Act of 2025
  • S. 2027
    Prescription Information Modernization Act of 2025
  • H.R. 8800
    National Defense Authorization Act for Fiscal Year 2027
  • S. 4784
    National Defense Authorization Act for Fiscal Year 2027
  • S. 3822
    Break Up Big Medicine Act
  • H.R. 10444
    Stop Corporate Takeovers of Physicians Act of 2026
  • S. 5419
    Stop Corporate Takeovers of Physicians Act of 2026
  • H.R. 2213
    Medical Supply Chain Resiliency Act

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.

Report a problem